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a  b  s  t  r  a  c  t
INTRODUCTION:  Phyllodes  tumors  (PTs)  of  the  breast  are extremely  rare  accounting  for  less  than  1%  of  all
breast  tumors  globally.  Case  records  at the  Trinidad  and  Tobago  Cancer  Registry  show  that  only  0.003%
of  the  reported  breast  cancer  cases  between  1995  and  2009  were  PTs.
PRESENTATION  OF  THE  CASE:  We  report  a 45-year-old  woman  who  presented  with  swelling  of  the  left
breast.  Ultrasound,  mammogram  and  computed  tomography  imaging  conﬁrmed  the  presence  of  a  mass
in the  right  upper  inner  quadrant  of  the  left  breast.  A biopsy  revealed  features  supportive  of  a benign
phyllodes  tumor.  A  wide  local  excision  was  performed  with  the  removal  of a 19  ×  11  × 10  cm  mass.
Histopathological  analysis  revealed  features  consistent  with  malignant  phyllodes  tumor.  A complete
mastectomy  of  the  left breast  was  subsequently  performed.  Follow  up  over  a 5-year  period  did not  reveal
any evidence  of local  recurrence  or  residual  disease.  To the  best  of our  knowledge,  this  is  the ﬁrst case
report  of a malignant  PT  from  the  Caribbean  and  Latin  America.
DISCUSSION:  Phyllodes  tumors  are  classiﬁed  as  benign,  borderline,  or  malignant  based  on  histologic  fea-
tures including  presence  of  a  clear  margin,  cellularity,  stromal  overgrowth,  tumor  necrosis  and  mitotic
index.  The  clinical  challenge  is  to  assess  the  risk  of  local  tumor  and  metastatic  recurrence  in  the  context
of  ﬂuid  classiﬁcations.
CONCLUSION:  Our  case  management  approach  shows  that for patients  with  malignant  PT, a thorough
preoperative  workup regimen  followed  by  appropriate  surgical  intervention  can  result in a desirable
prognosis.
© 2017  Published  by  Elsevier  Ltd on  behalf  of  IJS  Publishing  Group  Ltd.  This  is  an  open  access  article
under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Phyllodes tumors (PTs) of the breast are circumscribed bipha-
sic ﬁbroepithelial neoplasms analogous to ﬁbroadenomas [1]. PTs
are characterized by a double layered epithelial component sur-
rounded by a hypercellular mesenchymal component, typically
presenting in leaf-like processes [1]. These tumors are extremely
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rare, globally accounting for 0.3% to 1% of all breast tumors and
2.5% of all ﬁbroepithelial tumors of the breast [2]. They commonly
occur in women  35–55 years (median 45 years) [1].
The World Health Organization (WHO) classiﬁcation schema
grades PTs as benign, borderline, or malignant based on stromal
patterns of cellularity, nuclear atypia, mitotic activity, heterologous
stromal differentiation, stromal hypercellularity, cellular pleomor-
phism and tumor margin appearance [1]. However, absent clear
deﬁning boundaries for each of these histologic parameters, reliable
classiﬁcation assignment is challenging [3].
The majority (up to 60%) of PTs are benign [1]. Distant metas-
tases have been reported in up to 22% of malignant PTs with
expansion to nearly all internal organs, in particular the lung and
skeleton [3]. Axillary lymph node metastases are rare. Wide local
excision or mastectomy with appropriate margins is the preferred
clinical intervention [4].
https://doi.org/10.1016/j.ijscr.2017.09.021
2210-2612/© 2017 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Fig. 1. A) Transverse ultrasound image of the left breast demonstrates a heterogeneous, mostly hypoechoic mass (blue arrows), the full extent of which is not demonstrated
on  the images. B) Transverse ultrasound image of the left breast with color doppler interrogation demonstrates a heterogeneous, mostly hypoechoic mass with internal
vascularity (blue arrows), the full extent of the mass is not demonstrated on the images.
Fig. 2. Mammogram imaging of the left breast. A). The right craniocaudal view showing heterogeneously dense breast tissue with a fairly well deﬁned spherical opacity in
the  right upper inner quadrant (blue arrows). B). The left craniocaudal view showing a large mass 13 cm (AP) × 13 cm (TS) with lobulated margins replacing most of the left
breast  parenchyma (blue arrows). A few scattered foci of coarse, punctate and plaque-like calciﬁcations are seen within the mass centrally (red arrows).
We  describe the case of a 45-year-old woman who  presented
to the Eric Williams Medical Sciences Complex (EWMSC), Champ
Fleurs, Trinidad and Tobago (TT) with swelling of her left breast,
which was later conﬁrmed histologically to be a malignant phyl-
lodes tumor. This case report was prepared according to the
Surgical CAse REport (SCARE) guidelines which provides a frame-
work for accuracy in surgical case reports[5,6].
2. Case presentation
A 45-year-old woman of Trinidad and Tobago nationality and
East Indian ancestry, presented to the emergency room of the Eric
Williams Medical Sciences Complex (EWMSC) with a 3-week his-
tory of left breast swelling. She had a body mass index (BMI) of
31.8 kg/m2, and reported a history of diabetes mellitus type 2 and
hypertension. The patient also reported abstinence from smoking
and alcohol. She had four children, with the ﬁrst birth occurring at
26 years.
She reported that the swelling occurred a few days after being
accidentally hit on the left breast. Examination revealed a hard,
nodular 13 × 10 cm mass, with no palpable axillary lymph nodes.
An ultrasound revealed a heterogeneous, mostly hypoechoic mass
with internal vascularity (Fig. 1A, and B). A mammogram revealed
a heterogeneously dense breast tissue with a well-deﬁned spher-
ical opacity in the right upper inner quadrant (Fig. 2A). Further, a
large mass with lobulated margins replacing most of the left breast
parenchyma along with a few scattered foci of coarse, punctate
and plaque-like calciﬁcations were noted (Fig. 2B). These observa-
tions supported a clinical suspicion of phyllodes tumor. Computed
tomography (CT) imaging of the chest revealed a large lobulated
soft tissue density mass in the left breast (Fig. 3A–C).
An ultrasound-guided Tru-cut needle biopsy demonstrated fea-
tures such as high stromal cellularity with moderate pleomorphism
that would support a differential diagnosis of benign PT (Fig. 4).
Histopathological examination revealed that the needle core sec-
tions were composed of cellular-stromal spindle cell lesions with
hypocellular areas. The spindle cells showed mild pleomorphism,
with few mitosis <5/10 high power ﬁeld (hpf) and the tumor was
devoid of glandular elements or foci of necrosis. However, because
of heterogeneity of the tumor, wider sampling was considered
essential for comprehensive evaluation.
A few weeks later, the patient returned to the hospital com-
plaining of acute pain around the swelling. After counseling by the
case management team, the patient agreed to have the mass sur-
gically removed by wide excision. In brief, the patient was sterile
prepped, draped and an elliptical incision was made around the
affected area leaving 1 cm margins past the involved skin. Hemosta-
sis was  achieved using diathermy coagulation after the excision
and a silicone drain was  placed in situ. Her estimated blood loss
was 150 ml.  The deep tissues and skin were sutured with 2.0 vicryl
and 3.0 prolene (subcuticular stitch looped in the middle), respec-
tively. The operation was uneventful culminating with the excision
of the large mass which was invading the skin and superior areolar
complex. Postoperatively, the patient received divon (Diclofenac),
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Fig. 3. Images from a CT chest post IV contrast in the arterial phase and in soft tissue window without signiﬁcant enhancement post IV contrast administration. A). Axial
view.  Partially seen in the ﬁeld of view of the scan is a large lobulated soft tissue density mass in the left breast corresponding to the previously seen mammographic mass
(blue  arrows). The visualized portion measures 9 cm (AP) × 12 cm (TS). No enlarged axillary or internal mammary lymph nodes seen. B). Coronal image. Partially seen in the
ﬁeld  of view of the scan is a large lobulated soft tissue density mass in the left breast corresponding to the previously seen mammographic mass (blue arrows). Few central
calciﬁcations were observed (red arrow). The visualized portion measures 12 cm (TS) × 12 cm (Cranial-Caudal, CC). C) Para-sagittal image. Partially seen in the ﬁeld of view
of  the scan is a large lobulated soft tissue density mass in the left breast corresponding to the previously seen mammographic mass (blue arrows). The visualized portion
measures 9 cm (AP) × 12 cm (CC).
Fig. 4. Phyllodes tumor biopsy shows marked stromal cellularity with mild pleo-
morphism (Hematoxylin and eosin, H&E; 20×).
Invanz, Flagyl, an analgesic, and anti-embolism stocking. Ambula-
tion was encouraged.
A complete mastectomy of the left breast was  performed a few
weeks later. In brief, the patient was sterile prepped, draped and
Zinacef administered on induction. An incision made along the
elliptical line drawn from the clavicle to the 6th rib to the sternum to
the axillary tail. The breast was removed with deep margins includ-
ing pectoralis fascia. Hemostasis was achieved and suturing was as
for the prior surgery. Two silicone drains were placed in situ. Post-
operatively, the patient received divon, Rocephin, an analgesic, and
anti-embolism stocking. As before, ambulation was encouraged.
The excised specimen consisted of a large, ﬁrm oval mass
partly covered by an ellipse of skin, measuring 20 × 15 × 10 cm.
Cut sections revealed a ﬂeshy grey-white tumor measuring
19 × 11 × 10 cm with satellite nodules close to the inferior mar-
gin. Histopathological investigations revealed that sections showed
marked stromal cellularity with mild pleomorphism. Additionally,
a well circumscribed cellular stromal tumor containing occasional
glandular elements was observed. The epithelial component in
the adjoining tissue and tumor showed ductal and lobular hyper-
plasia and focal in situ carcinoma (Fig. 5). There were foci of
tumor necrosis, mild-moderate atypia foci of marked cellularity
resembling ﬁbrosarcoma with a mitotic index >5/10 hpf in the
active areas (Fig. 6). No evidence of lympho-vascular invasions
was observed. The tumor showed a predominately pushing growth
Fig. 5. Phyllodes tumor. Glandular elements showing duct hyperplasia at the
periphery of the tumor (black arrow head). (H&E;10×).
pattern (Fig. 7). The medial, superior, and inferior margins were
not clear. However, the posterior margin was clear but showed a
breach in the capsule, while the lateral and anterior margins were
close (<3 mm)  but clear. These histologic features are consistent
with the WHO  grading for a malignant phyllodes tumor. Sections
from the mastectomy specimen showed granulomatous inﬂamma-
tory changes. Residual tumor was  not observed in the lesion and all
margins were clear.
At her bimonthly follow up appointment, Tramacet was  pre-
scribed to alleviate the intermittent pain around the incision site.
She had an uneventful postoperative course and ten months later a
surveillance CT did not reveal any recurrent or residual mass (Fig. 8).
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Fig. 6. Phyllodes tumor. Cellular stroma shows brisk mitoses (black arrow heads).
(H&E; 40×).
Fig. 7. Tumor showing a pushing growth pattern.
After a three-year absence, the patient returned to the clinic and
a surveillance abdomen/pelvis and chest CT imaging regimen did
not reveal any evidence of local recurrence or residual disease. A
technetium 99 m (99mTc) hydroxyethylene diphosphonate (HDP)
bone scan with anterior and posterior imaging was negative for
uptake in the lumbar vertebral region which would have been sug-
gestive of metastatic deposits. Stable disease with stable sclerotic
lesions were observed in her lumbar vertebral bodies.
An exhaustive PubMed/Medline and EMBASE medical database
search from inception (1946) to present was performed. The search
strategy was created using indexing terms/keywords and the AND
Boolean operator. For example; in PubMed: (Caribbean OR Latin
America OR developing countries) AND (phyllodes tumor OR cys-
tosarcoma phylloides). After limiting ﬁnal retrieval to English
language; humans and case reports; we retrieved one citation for
a benign PT [7]. To the best of our knowledge; ours is the ﬁrst
case report of a malignant PT in the Caribbean and Latin America.
A search of the TT Cancer Registry records revealed that only 12
(0.003%) of the 4685 reported breast cancer cases between 1995
and 2009 were phyllodes tumors (Table 1). All of the cases were
malignant with most patients (11/12; 1 unknown) receiving only
surgical intervention. The mean age at presentation was  49.
3. Discussion
In this case, there was a high degree of suspicion for a benign
PT based in part, on the biopsy ﬁndings of few mitoses. How-
ever, histopathological examination of the mass revealed that the
mitoses in active areas were >5/10hpf and thus strongly suggestive
of malignant PT. Extensive imaging and histopathological workup
is critical when a diagnosis of PT is suspected [8]. If the mass
has a smooth contours, intramural cysts and low echogenicity on
ultrasound, a PT is usually suspected and a core needle biopsy
recommended [9,10]. In such cases, cytology specimens should
contain both epithelial and stromal elements to conﬁrm the PT
diagnosis. However, there is oftentimes discordance between the
core biology pathology and surgical histopathology in rendering a
differential diagnosis between the various classiﬁcations of PT and
ﬁbroadenoma due to tumor heterogeneity [11,12].
All of the cases reported to the TT Cancer Registry since 1995
were classiﬁed as malignant. This is striking given that globally
most PTs are benign. Distinguishing between benign, borderline,
and malignant PT is critical to the development of an effective
clinical management plan. There is signiﬁcant variability in the
interpretation of the criteria for each designation. Additionally,
tumor heterogeneity, sampling errors increase reported variabil-
ities. In fact, studies in which different pathologists have analyzed
the same histological slides were marked by a 25% discordance
in the ﬁnal histopathological ﬁnding [13]. One  approach to bet-
ter delineate between benign and a malignant PT might be to
assess the immunohistochemical (IHC) expression of CD10 in the
stromal cells. CD10 immunoreactivity has the potential to inform
on the histopathological grading of PTs, given that CD10 expres-
sion strongly correlates with PT grade [14,15]. Restaging with
18F-ﬂuorodeoxyglucose positron emission tomography computed
tomography (FDG PET-CT) could also be helpful in distinguish-
ing between a benign and malignant PT [8]. This hybrid imaging
modality beneﬁts from the sensitivity of the PET component and
the speciﬁcity of the CT component. However, it is not available
in the Caribbean or most low resource countries. The challenges
Fig. 8. Selected images of a CT chest post IV contrast in the arterial phase and in soft tissue window. A). Axial view B). Coronal view. C). Sagittal view showing post-surgical
changes  noted (left mastectomy) with no recurrent/residual masses seen (blue arrow).
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Table  1
Reported phyllodes tumor of the breast cases in Trinidad and Tobago,1995–2017.
Ethnicity Age at
incidence
Basis of diagnosis Stage Classiﬁcation Surgery Chemotherapy Status at last
contact
Follow up period Source
Mixed 42 Histology of primary Localized Malignant Yes No Alive 1 year TT Cancer Registry
Unknown 40 Histology of primary Localized Malignant Yes No Alive 2 years TT Cancer Registry
African 57 Histology of primary Unknown Malignant No No Expired 1 year TT Cancer Registry
Mixed  73 Histology of primary Regional Malignant Yes No Alive 1 year TT Cancer Registry
Indian  49 Histology of primary Localized Malignant Yes No Alive 2 years TT Cancer Registry
Unknown 61 Histology of primary Localized Malignant Yes No Alive 1 year TT Cancer Registry
African 43 Histology of primary Regional Malignant Yes No Alive 1 year TT Cancer Registry
Indian  54 Histology of primary Localized Malignant Yes No Alive 1 year TT Cancer Registry
Indian  51 Histology of primary Unknown Malignant Unknown Unknown Unknown None TT Cancer Registry
Indian  45 Histology of primary Distant Malignant Yes No Alive 1 year TT Cancer Registry
Mixed  49 Histology of primary Localized Malignant Yes No Unknown None TT Cancer Registry
Indian  29 Histology of primary Localized Malignant Yes No Alive 4 years TT Cancer Registry
Indian  44 Histology of primary – Benign Yes No Expired 6 months post-surgery [7]
Indian 45 Histology of primary – Benign Yes No Alive 4 years This case
*Ethnicity was  self-reported. These categories are based on physical observation without any assessment of genetic variants. Indian refers to ancestry from India, South Asia.
All  patients were nationals of TT.
of expanding nuclear medicine capacity in low resource countries
were reviewed elsewhere [16,17]. The addition of FDG PET-CT to
the diagnostic arsenal might be of value in developing countries
given the increasing cancer burden.
While the molecular basis of phyllodes tumors largely remains
unknown, the most frequent genomic insults are mutations in exon
2 of MED12, a subunit of the transcriptional mediator complex and
RARA [18–20]. Interestingly, ﬁbroadenomas also share this genetic
signature [18–20]. Less frequently, mutations in FLNA, SETD2 and
KMT2D have also been reported in PT. Loss of function mutations
in p53, deleterious mutations in Rb1 and NF1, mutations in PIK3CA
and ERBB4,  and high-level copy number variations of EGFR were
detected in borderline and malignant tumors [20]. However, EGFR
and IGF1R gene ampliﬁcations were only detected in malignant
tumors [21,22]. These mutational signatures of PT provide a possi-
ble framework to distinguish between the three subtypes. This type
of genome forward clinical assessment is not available in Trinidad
and Tobago and the Caribbean region, in general. Capacity building
towards this level of precision medicine is ﬁscally challenging for
the region, but is crucial for long term sustainable improvements
in health care [23].
Breast-conserving surgery with appropriate margins (≥1 cm)  is
the preferred primary therapy for PT in the absence of metastatic
disease [4]. In this case, given the histologic conﬁrmation of a
malignant tumor, we elected to perform a wide excision in accor-
dance with National Comprehensive Cancer Network guidelines
[24] followed by a mastectomy. Axillary dissection was not per-
formed since nodal metastases secondary to PT are very rare.
The utility of adjuvant therapy in the management of PT cases is
unclear and there are no prospective or randomized studies of adju-
vant chemotherapy in this setting. Recent reports recommended
adjuvant therapy intervention for borderline cases with maximal
diameter greater than 5 cm and those with histologic evidence of
stromal overgrowth, since these seem to have greater metastatic
potential [4,25]. For metastatic PTs, some studies have reported
promising results with administration of ifosfamide, doxorubicin
and dacarbazine [26,27].
Given the absence of metastasis or recurrence in the chest wall
post mastectomy, radiotherapy was not offered to this patient. In
fact, there are no prospective randomized data in support of radio-
therapy for PT [24]. Recent studies advocate the use of radiotherapy
for borderline and malignant PT, recurrent tumors and in cases
where it is not possible to achieve a greater than one-centimeter
surgical margin [25,28]. Given the rarity of PT, it might be challeng-
ing to derive a randomized controlled trial with adequate sample
size.
4. Conclusion
Phyllodes tumors are extremely rare. The major challenge fac-
ing clinicians in developing countries is the availability of clinical
resources to adequately distinguish between ﬁbroadenoma and PT,
and where PT is afﬁrmed, to arrive at the appropriate PT classiﬁ-
cation. Our experience with this case in TT shows that adequate
preoperative workup followed by surgical intervention can result
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